The head of an Indian company contracted to make AstraZeneca's coronavirus vaccine said it could deliver it to healthcare workers and elderly Indians by January, as reported in London South East.
The Serum Institute of India (SII) has already manufactured millions of doses of the vaccine that is being developed in collaboration with Oxford University while results from late-stage trials are awaited.
Adar Poonawaala, the chief executive of the SII, said that his company would seek emergency-use authorisation for the AstraZeneca vaccine as soon as authorities in the UK approved it and made it available for the general public.
"It's been a Herculean task and we are very happy now that we are almost now on autopilot waiting just for the vaccine results to come," Poonawaala said, adding "then we can churn out hundreds of millions more of the vaccine."
The vaccine would be priced between $5 to 6 in the retail market, but the Indian government would get it for much less, because they would buy it in bulk, Poonawaala said.
The executive also suggested it would take at least two to three years for all of India's 1.3 billion population to be covered.
To read more NewsPoints articles, click here.